Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 2/20 | 0.45 |
| ▸ | GLI1 | P08151 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 3/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 2/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3632516 | 1.00 | SCN4A (0.46) | SCN4APRCPGLI1DPP4DPP7 | |
| Hydrochloric Acid SCHEMBL1190797 | 0.98 | SCN4A (0.45) | SCN4APRCPGLI1DPP4DPP7 | |
| Hydrochloric Acid SCHEMBL15847061 | 0.98 | SCN4A (0.45) | SCN4APRCPGLI1DPP4DPP7 | |
| SCHEMBL4153806 | 0.94 | SCN4A (0.42) | SCN4APRCPGLI1DPP4DPP7 | |
| SCHEMBL7500478 | 0.85 | PRCP (0.46) | SCN4APRCPGLI1DPP4DPP7 | |
| SCHEMBL3330058 | 0.83 | SCN4A (0.49) | SCN4APRCPGLI1DPP4DPP7 | |
| SCHEMBL10827185 | 0.82 | PRCP (0.51) | SCN4APRCPGLI1DPP7NOS2 | |
| SCHEMBL9288424 | 0.81 | LMNA (0.51) | SCN4AALDH1A1 | |
| Hydrochloric Acid SCHEMBL9439145 | 0.80 | PRCP (0.52) | SCN4APRCPGLI1DPP7 | |
| SCHEMBL26477623 | 0.79 | SCN4A (0.42) | SCN4APRCPGLI1DPP4DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948167-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES, LTD. (IN) | 2008-07-30 | — | — | EP | claimed |
| WO-2007045980-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | WO | claimed |
| EP-4496792-A1 | SMALL-MOLECULE INHIBITORS TARGETING THE BOB1/OCT1 INTERFACE | Nantes Université (FR) | 2025-01-29 | — | — | EP | disclosed |
| CN-112745298-B | Polysubstituted isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-04-09 | — | — | CN | disclosed |
| EP-3334710-B1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEURODEGENERATIVE DISORDERS | ALZHEON INC (US) | 2023-10-04 | — | — | EP | disclosed |
| WO-2023180387-A1 | SMALL-MOLECULE INHIBITORS TARGETING THE BOB1/OCT1 INTERFACE | NANTES UNIVERSITE (FR) | 2023-09-28 | — | — | WO | disclosed |
| US-11548891-B1 | Quaternary ammonium salts of phenanthroindolizidine and phenanthroquinolizidine alkaloids as hypoxia-targeted anticancer agents | BATTERJEE MEDICAL COLLEGE (SA) | 2023-01-10 | — | — | US | disclosed |
| CN-112745298-A | Polysubstituted isoindoline compound, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2021-05-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548891-B1 | Quaternary ammonium salts of phenanthroindolizidine and phenanthroquinolizidine alkaloids as hypoxia-targeted anticancer agents | H1-3, H1-4, H1-2 | SCN4A 717/4885PRCP 1216/4885GLI1 914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.